arrow
F

Fabio Marra

University of Florence
H指数:92
被引数:2.9万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores

在采用阿替利珠单抗/贝伐珠单抗治疗的肝癌患者中分层心血管风险:ESC评分与CARDIOSOR评分的比较

2026-10-070
OAAI
Pre-Treatment Serum Albumin Concentration Predicts Clinical Benefit of Long-Term Albumin in Patients With Cirrhosis and Ascites

术前血清白蛋白浓度预测肝硬化伴腹水患者长期输注白蛋白的临床获益

2026-07-300
OAAI
Vessels Encapsulating Tumor Clusters predict better outcomes in advanced hepatocellular carcinoma treated with atezolizumab–bevacizumab

包裹肿瘤簇的血管可预测接受阿替利珠单抗–贝伐珠单抗治疗的晚期肝细胞癌的更好预后

2026-04-290
OAAI
Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma

血清降钙素原: 诊断和监测纤维板层肝癌的新型肿瘤生物标志物

2026-02-060
PRE
Health-care burden of metabolic dysfunction-associated steatotic liver disease in European tertiary-care outpatient clinics (CONSTANS): a prospective multicentre cohort study

欧洲三级保健门诊中代谢功能障碍相关脂肪性肝病的医疗负担(CONSTANS):一项前瞻性多中心队列研究

2026-01-010
OA
Neoadjuvant Under-Dilated TIPS: Expanding Surgeries for Extrahepatic Malignancies in Patients With Cirrhosis and CSPH

新辅助性未扩张经颈静脉肝内门体分流术:为肝硬化合并显著门静脉高压患者扩展外科手术适应症以治疗肝外恶性肿瘤

2025-12-090
OAAI
Shunt magnitude is a key determinant of overt hepatic encephalopathy in patients undergoing TIPS

分流量是门体分流术后显性肝性脑病的关键决定因素。

2025-11-110
OAAI
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab

丙型肝炎清除可改善接受阿替利珠单抗联合贝伐珠单抗治疗患者的肿瘤学和临床结局

2025-09-220
PREAI
The DNA Minor Groove Binders Trabectedin and Lurbinectedin Are Potent Antitumor Agents in Human Intrahepatic Cholangiocarcinoma

DNA小沟结合剂Trabectedin和Lurbinectedin是人类肝内胆管癌的强效抗肿瘤剂

2025-09-210
OAAI
ITA-MASLD: A national observational study to characterize the profile of patients with MASLD in specialistic care in Italy

ITA-MASLD:一项全国性观察性研究,旨在描述意大利专科医疗中MASLD患者的特征。

2025-09-150
PRE
Outcome of hepatic resection for HCC in ideal and non-ideal candidates

理想和非理想候选者行肝切除治疗HCC的结局

2025-07-290
OA
Impact of first and further decompensation in patients with compensated ACLD due to MASLD

首次和进一步失代偿对由于MASLD导致的代偿性ACLD患者的影响

2025-06-210
OAAI
Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study

肝细胞癌患者接受阿替利珠单抗联合贝伐珠单抗治疗后肝功能失代偿:一项真实世界研究

2025-02-260
OAAI
Efficacy and safety of atezolizumab/bevacizumab for hepatocellular carcinoma in a real-life prospective cohort: A 2024 update
2025-02-010
PRE
The impact of first and further decompensation in patients with metabolic-dysfunction associated compensated advanced chronic liver disease
2025-02-010
PRE
Predictors of esophago-gastric varices and variceal bleeding in patients receiving atezolizumab/bevacizumab for unresectable hepatocellular carcinoma
2025-02-010
PRE